You Won’t See Me, But the Government Will: How the Corporate Transparency Act Affects Life Sciences Companies

Event Details

The Corporate Transparency Act (“CTA”) was enacted in 2019, but the reporting requirements under the CTA took effect January 1, 2024. Although certain entities are exempt from filing beneficial owner reports (“Reports”) with the Financial Crimes Enforcement Network (“FinCEN”), most legal entities formed in the United States or a U.S. territory, as well as those authorized to do business in a U.S. state or territory, will be required to file Reports with FinCEN. Please join AGG Private Wealth partner Michael L. Van Cise and AGG Tax attorney Garrett A. Brown for a complimentary webinar as they discuss how the CTA may affect life sciences companies. AGG Food & Drug co-chair Alan Minsk will serve as moderator.

During the webinar, Michael, Garrett, and Alan will discuss:

• The requirement to file Reports with FinCEN and the civil and criminal penalties for failure to comply
• The exceptions to filing requirements most relevant for life science companies
• Who is considered a “senior officer” (and therefore obligated to file Reports)
• Who is considered a “beneficial owner”
• Strategies to minimize the reporting burden or ensure that an exception is met
• Clauses to consider in governing documents

There will be an opportunity for Q&A at the end of this webinar.

Credits: 1 hour of CLE credit is approved by the State Bar of Georgia

To enhance your webinar experience with us, please make sure to access the webinar from outside of a VPN and close out of all other streaming services. The webinar is best viewed on a desktop or laptop computer. The recommended browser is Google Chrome.

Please click here to perform an automatic system check to confirm your system is compatible with the webinar.

Please click here to view the GoToWebinar attendee guide.

Recording

To watch a recording of the webinar, please click here.